Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Feb 25;4(2):e978709. doi: 10.4161/2162402X.2014.978709

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Taylor & Francis Group, LLC

PMC Copyright notice

Figure 6. — Chemokine presentation on GU tumor stroma differs from that in skin tumor stroma. Genitourinary (GU) and cutaneous tumor-bearing RETAAD mice were treated with Temazolomide (TMZ) or dimethyl sulfoxide (DMSO) vehicle. (A) Flow cytometry analysis to evaluate intracellular CXCL9 and CXCL10 expression by GU and skin tumor-associated fibroblasts (TAFs) at day 10 after DMSO or TMZ treatment. (B) Flow cytometry assessment of CXCL9 and CXCL10 expression by TAFs from skin and GU tumors after DMSO or TMZ treatment. (C) High magnification immunofluorescence images were obtained to examine CXCL9 and CXCL10 protein expression on GU and skin tumor stroma. Data from (A) and (B) are representative of and pooled from 2 separate experiments with 3 mice per group in each experiment (n = 6/group). Images from (C) are representative of 5 independent experiments (n = 5/group). Scale bars in (C) represent 50 μm.